ArticlePloS one2019
Biofabrication of streptomycin-conjugated calcium phosphate nanoparticles using red ginseng extract and investigation of their antibacterial potential.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Article
Corrections and comments
- Retraction · 2020-01-21Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Conflict of Interest · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjugation of nanoparticles (NPs) with antibiotics for treating multidrug resistant pathogens has been enormously studied now a days. In the current investigation, calcium phosphate (CaP) NPs were produced by co-precipitation using red ginseng extract as the reducing agent and were conjugated to the antibiotic streptomycin to form streptomycin-conjugated NPs (CPG-S NPs). The CPG-S NPs antibacterial activity was evaluated in this study against eight plant and five foodborne pathogenic bacteria. The synthesized CPG-S NPs were characterized by UV-VIS spectroscopy, scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy, Fourier-transform infrared spectroscopy, X-ray powder diffraction, and thermogravimetric and differential thermogravimetric analysis. CPG-S NPs exhibited promising antibacterial activity against all eight plant pathogenic bacteria and three of the five foodborne pathogenic bacteria tested; the diameter of inhibition zones ranged between 9.74-16.95 mm and 9.82-15.84 mm, respectively. CPG-S NPs displayed 50-100 μg/mL of minimum inhibitory concentration and 100 μg/mL of minimum bactericidal concentration against the plant and foodborne pathogenic bacterial strains, respectively. Furthermore, the SEM image of bacteria treated with CPG-S NPs displayed cells with a ruptured cell wall and fewer cells compared to the SEM image of untreated control bacteria displaying uniform and intact cells. SEM confirmed that CPG-S NPs degraded the bacterial cell wall and membrane resulting in lysed bacterial cells. In conclusion, the results suggest that CPG-S NPs could be effectively utilized in formulating drugs to treat bacterial plant or dental diseases and in manufacturing dental products such as toothpaste, mouthwashes, and artificial teeth.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.